Items where authors include "Nam, J.H."

Article

Lee, J.E. orcid.org/0000-0001-6173-2748, Nam, J.H., Kwon, S.H. orcid.org/0000-0002-1058-8392 et al. (2 more authors) (2024) Real‐world evidence of brigatinib as second‐line treatment after crizotinib for ALK+ non‐small cell lung cancer using South Korean claims data (K‐AREAL). Cancer Medicine, 13 (14). e70030. ISSN 2045-7634

Lee, J.-E., Kwon, S.-H. orcid.org/0000-0002-1058-8392, Kwon, S. et al. (3 more authors) (2023) Concomitant use of proton pump inhibitors and palbociclib among patients with breast cancer. JAMA Network Open, 6 (7). e2324852. ISSN 2574-3805

Oh, B.-C., Cho, A.-R., Nam, J.H. et al. (4 more authors) (2023) Survival differences between patients with de novo and relapsed/progressed advanced non-small cell lung cancer without epidermal growth factor receptor mutations or anaplastic lymphoma kinase rearrangements. BMC Cancer, 23. 482. ISSN 1471-2407

Park, H.-Y. orcid.org/0000-0001-8348-0887, Kwon, J.-W. orcid.org/0000-0003-3467-7805, Kim, H.-L. orcid.org/0000-0001-9091-8787 et al. (6 more authors) (2023) Cost-effectiveness of all-oral regimens for the treatment of multidrug-resistant tuberculosis in Korea: comparison with conventional injectable-containing regimens. Journal of Korean Medical Science, 38 (21). e167. ISSN 1011-8934

Jang, S.-C. orcid.org/0000-0002-6220-7635, Nam, J.H. orcid.org/0000-0003-2165-5287, Lee, S.-A. orcid.org/0000-0002-4093-7928 et al. (4 more authors) (2022) Clinical manifestation, economic burden, and mortality in patients with transthyretin cardiac amyloidosis. Orphanet Journal of Rare Diseases, 17 (1). 262. ISSN 1750-1172

Kwon, S.-H. orcid.org/0000-0002-1058-8392, Nam, J.H., Kim, H.-L. et al. (2 more authors) (2022) Real-world association of adherence with outcomes and economic burden in patients with tuberculosis from South Korea claims data. Frontiers in Pharmacology, 13. 918344. ISSN 1663-9812

Yang, S.-Y. orcid.org/0000-0002-6850-3486, Kang, D.-W. orcid.org/0000-0002-7088-867X, Nam, J.H. orcid.org/0000-0003-2165-5287 et al. (4 more authors) (2022) Adherence is an optimal factor for maximizing the effective and safe use of oral anticoagulants in patients with atrial fibrillation. Scientific Reports, 12 (1). 3413. ISSN 2045-2322